Literature DB >> 7712463

Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men.

H Takahashi1, M Furusato, W C Allsbrook, H Nishii, S Wakui, J C Barrett, J Boyd.   

Abstract

The incidence rate of clinically apparent prostatic carcinoma is 8-fold higher in the United States than in Japan, while the prevalence of latent prostatic carcinoma, a presumed precursor to clinical carcinoma, is similar in the two countries. The purpose of this study was to investigate the hypothesis that this profound difference in incidence rates of clinical carcinoma reflects distinct profiles of molecular genetic alterations in the latent precursor lesions that occur in the two countries. A significant fraction of latent carcinomas from Japanese men were found to contain inactivating mutations of the androgen receptor gene, while no such mutations were found in latent carcinomas from American men. No mutations were found in clinical carcinomas from either country. These data offer a potential molecular genetic explanation that may partially account for the distinct prostatic carcinoma incidence rates in these two populations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712463

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

3.  The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process.

Authors:  Pierre Chymkowitch; Nicolas Le May; Pierre Charneau; Emmanuel Compe; Jean-Marc Egly
Journal:  EMBO J       Date:  2010-12-14       Impact factor: 11.598

Review 4.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 5.  Androgen-receptor gene structure and function in prostate cancer.

Authors:  J M Hakimi; R H Rondinelli; M P Schoenberg; E R Barrack
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 6.  Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy.

Authors:  Z Culig; A Hobisch; A Hittmair; M V Cronauer; C Radmayr; G Bartsch; H Klocker
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

Review 7.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

8.  Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.

Authors:  K V Honn; A Aref; Y Q Chen; M L Cher; J D Crissman; J D Forman; X Gao; D Grignon; M Hussain; A T Porter; J E Pontes; I Powell; B Redman; W Sakr; R Severson; D G Tang; D P Wood
Journal:  Pathol Oncol Res       Date:  1996-03       Impact factor: 3.201

Review 9.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

10.  The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity.

Authors:  Colin W Hay; Iain J McEwan
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.